Title |
Combination Therapy for Patients with Choroidal Neovascularization (CNV) |
| MEEI Protocol ID | 09-10-101 |
| National Clinical Trial (NCT) Number | NCT01256580 |
|
Condition
|
Choroidal Neovascularization (CNV) due to causes other than Age-Related Macular Degeneration
|
|
Sponsor
|
Massachusetts Eye and Ear Infirmary
|
|
Principal Investigator
|
Ivana Kim, M.D.
|
|
Study Design
|
This is a Phase I single center, unmasked, randomized clinical trial
|
|
Study Objective
|
To compare the efficacy of Avastin alone to combination therapy with Avastin, photodynamic therapy (PDT), and dexamethasone for patients with choroidal neovascularization (CNV) secondary to causes other than age-related macular degeneration. These medications have anti-angiogenic and anti-inflammatory properties which may reduce or prevent the vision loss associated with the development of CNV. Combination therapy may enhance the beneficial effect of these drugs.
|
|
Who is Eligible
|
Individuals, at least 18 years of age, with a clinical diagnosis of choroidal neovascularization secondary to any cause other than age-related macular degeneration. Previous treatment with photodynamic therapy, laser photocoagulation, intraocular steroids, or other anti-angiogenic compounds is allowed but must have been performed more than 30 days before entering the study.
|
|
Subject Enrollment
|
We are currently enrolling individuals with CNV who meet all study criteria.
|
|
Study Procedures
|
Qualified patients will be randomly assigned to receive intravitreal injections of Avastin or combination therapy for a period of 12 months. Patients will be followed monthly throughout the study period to determine the need for treatment.
|
|
For More Information
|
Jacqueline Sullivan, Study Coordinator
617-573-3920
|
Click here to return to the Ophthalmology Clinical Research page.
Page updated 8/6/2012.
